Cite

HARVARD Citation

    Navid, F. et al. (n.d.). A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. International journal of cancer. 141 (7), pp. 1469-1477. [Online]. 
  
Back to record